# First Merchants Corp: financial statements, quarterly

FRME · Nasdaq · CIK 712534 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/frme.md) · [Financials](/companies/frme/financials.md) · [Filings](/companies/frme/filings.md) · [Insiders](/companies/frme/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/frme/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense | $m | [83.5](/filings/0000712534-23-000196.md) | [95.8](/filings/0000712534-23-000294.md) | [107 d](/filings/0000712534-24-000071.md) | [109](/filings/0000712534-24-000162.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [10.7](/filings/0000712534-24-000243.md) | [9.0](/filings/0000712534-24-000341.md) | [4.4 d](/filings/0000712534-26-000022.md) | [6.8](/filings/0000712534-25-000117.md) | [4.1](/filings/0000712534-25-000171.md) | [7.2](/filings/0000712534-25-000197.md) | [12.3 d](/filings/0000712534-26-000022.md) | [7.9](/filings/0000712534-26-000035.md) | [8.3](/filings/0000712534-25-000171.md) | [8.5](/filings/0000712534-25-000197.md) | [8.4 d](/filings/0000712534-26-000022.md) | [(1.1)](/filings/0000712534-26-000035.md) |
| Net income | $m | [60.9](/filings/0000712534-24-000243.md) | [56.4](/filings/0000712534-24-000341.md) | [42.5 d](/filings/0000712534-26-000022.md) | [47.9](/filings/0000712534-25-000117.md) | [39.9](/filings/0000712534-25-000171.md) | [49.2](/filings/0000712534-25-000197.md) | [64.3 d](/filings/0000712534-26-000022.md) | [55.3](/filings/0000712534-26-000035.md) | [56.8](/filings/0000712534-25-000171.md) | [56.8](/filings/0000712534-25-000197.md) | [57.1 d](/filings/0000712534-26-000022.md) | [28.2](/filings/0000712534-26-000035.md) |
| Diluted EPS | $ per share | [1.02](/filings/0000712534-24-000243.md) | [0.94](/filings/0000712534-24-000341.md) | not reported | [0.80](/filings/0000712534-25-000117.md) | [0.68](/filings/0000712534-25-000171.md) | [0.84](/filings/0000712534-25-000197.md) | not reported | [0.94](/filings/0000712534-26-000035.md) | [0.98](/filings/0000712534-25-000171.md) | [0.98](/filings/0000712534-25-000197.md) | not reported | [0.45](/filings/0000712534-26-000035.md) |
| Basic EPS | $ per share | [1.02](/filings/0000712534-24-000243.md) | [0.95](/filings/0000712534-24-000341.md) | not reported | [0.80](/filings/0000712534-25-000117.md) | [0.68](/filings/0000712534-25-000171.md) | [0.84](/filings/0000712534-25-000197.md) | not reported | [0.95](/filings/0000712534-26-000035.md) | [0.98](/filings/0000712534-25-000171.md) | [0.98](/filings/0000712534-25-000197.md) | not reported | [0.46](/filings/0000712534-26-000035.md) |

- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $bn | [18.0](/filings/0000712534-23-000196.md) | [18.0](/filings/0000712534-23-000294.md) | [18.4](/filings/0000712534-25-000058.md) | [18.3](/filings/0000712534-24-000162.md) | [18.3](/filings/0000712534-24-000243.md) | [18.3](/filings/0000712534-24-000341.md) | [18.3](/filings/0000712534-26-000022.md) | [18.4](/filings/0000712534-25-000117.md) | [18.6](/filings/0000712534-25-000171.md) | [18.8](/filings/0000712534-25-000197.md) | [19.0](/filings/0000712534-26-000035.md) | [21.1](/filings/0000712534-26-000035.md) |
| Total liabilities | $bn | [15.8](/filings/0000712534-23-000196.md) | [15.9](/filings/0000712534-23-000294.md) | [16.2](/filings/0000712534-25-000058.md) | [16.1](/filings/0000712534-24-000162.md) | [16.1](/filings/0000712534-24-000243.md) | [16.0](/filings/0000712534-24-000341.md) | [16.0](/filings/0000712534-26-000022.md) | [16.1](/filings/0000712534-25-000117.md) | [16.2](/filings/0000712534-25-000171.md) | [16.4](/filings/0000712534-25-000197.md) | [16.6](/filings/0000712534-26-000035.md) | [18.4](/filings/0000712534-26-000035.md) |
| Shareholders' equity | $bn | [2.1](/filings/0000712534-24-000341.md) | [2.1](/filings/0000712534-24-000341.md) | [2.2](/filings/0000712534-26-000022.md) | [2.2](/filings/0000712534-25-000171.md) | [2.2](/filings/0000712534-25-000197.md) | [2.3](/filings/0000712534-25-000197.md) | [2.3](/filings/0000712534-26-000035.md) | [2.3](/filings/0000712534-26-000035.md) | [2.3](/filings/0000712534-25-000197.md) | [2.4](/filings/0000712534-25-000197.md) | [2.5](/filings/0000712534-26-000035.md) | [2.7](/filings/0000712534-26-000035.md) |

- Cash and equivalents: not reported
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [25.4 d](/filings/0000712534-24-000243.md) | [80.2 d](/filings/0000712534-24-000341.md) | [65.6 d](/filings/0000712534-26-000022.md) | [58.8](/filings/0000712534-25-000117.md) | [63.0 d](/filings/0000712534-25-000171.md) | [76.8 d](/filings/0000712534-25-000197.md) | [67.5 d](/filings/0000712534-26-000022.md) | [61.7](/filings/0000712534-26-000035.md) | [53.7 d](/filings/0000712534-25-000171.md) | [87.6 d](/filings/0000712534-25-000197.md) | [80.7 d](/filings/0000712534-26-000022.md) | [58.6](/filings/0000712534-26-000035.md) |
| Dividends paid | $m | [20.3 d](/filings/0000712534-24-000243.md) | [20.3 d](/filings/0000712534-24-000341.md) | [20.3 d](/filings/0000712534-26-000022.md) | [20.2](/filings/0000712534-25-000117.md) | [20.5 d](/filings/0000712534-25-000171.md) | [20.5 d](/filings/0000712534-25-000197.md) | [20.5 d](/filings/0000712534-26-000022.md) | [20.5](/filings/0000712534-26-000035.md) | [20.8 d](/filings/0000712534-25-000171.md) | [20.8 d](/filings/0000712534-25-000197.md) | [20.8 d](/filings/0000712534-26-000022.md) | [22.8](/filings/0000712534-26-000035.md) |
| Share repurchases | $m | [0.0 d](/filings/0000712534-24-000243.md) | [0.0 d](/filings/0000712534-24-000341.md) | [0.0 d](/filings/0000712534-26-000022.md) | [30.0](/filings/0000712534-25-000117.md) | [20.0 d](/filings/0000712534-25-000171.md) | [0.0 d](/filings/0000712534-25-000197.md) | [6.2 d](/filings/0000712534-26-000022.md) | [7.9](/filings/0000712534-26-000035.md) | [22.1 d](/filings/0000712534-25-000171.md) | [6.5 d](/filings/0000712534-25-000197.md) | [10.4 d](/filings/0000712534-26-000022.md) | [24.9](/filings/0000712534-26-000035.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [59.3](/filings/0000712534-23-000196.md) | [59.3](/filings/0000712534-23-000294.md) | [59.4](/filings/0000712534-24-000162.md) | [59.4](/filings/0000712534-24-000243.md) | [59.5](/filings/0000712534-24-000341.md) | [59.3](/filings/0000712534-25-000117.md) | [58.3](/filings/0000712534-25-000171.md) | [58.3](/filings/0000712534-25-000197.md) | [58.2](/filings/0000712534-26-000035.md) | [57.8](/filings/0000712534-25-000171.md) | [57.4](/filings/0000712534-25-000197.md) | [61.0](/filings/0000712534-26-000035.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 63,022,741 at 2026-04-27, from the cover of the [10-Q filed 2026-05-01](/filings/0000712534-26-000035.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.